Clarus Reports Third Quarter 2017 Results and Raises Full-Year Outlook
Nov 06, 2017 21:05 pm UTC| Business
SALT LAKE CITY, Nov. 06, 2017 -- Clarus Corporation (NASDAQ:CLAR) (“Clarus” and/or the “Company”), a diversified holding company which seeks opportunities to acquire and grow businesses that can generate attractive...
Gaia Reports Third Quarter 2017 Results
Nov 06, 2017 21:05 pm UTC| Business
BOULDER, Colo., Nov. 06, 2017 -- Gaia, Inc. (NASDAQ:GAIA), a conscious media company, reported financial results for the third quarter ended September 30, 2017. Third Quarter 2017 vs. Same Year-Ago Quarter 73%...
Flexion Therapeutics Reports Third-Quarter 2017 Financial Results and Recent Business Highlights
Nov 06, 2017 21:05 pm UTC| Business
ZilrettaTM (triamcinolone acetonide extended-release injectable suspension) received FDA approval for the management of osteoarthritis (OA) knee pain on October 6, 2017Product was made commercially available on October 23,...
MRI Interventions, Inc. Reports 26% Year-Over-Year Increase in Third Quarter Procedures
Nov 06, 2017 21:05 pm UTC| Business
Gross Margin Increases to 60% Record 469 ClearPoint Procedures Performed Year-to-Date IRVINE, Calif., Nov. 06, 2017 -- MRI Interventions, Inc. (OTCQB:MRIC) (the “Company”) today announced financial results for the...
TRACON Pharmaceuticals to Present at Upcoming Investment Conferences
Nov 06, 2017 21:05 pm UTC| Business
SAN DIEGO, Nov. 06, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related...
TrueCar Reports Third Quarter 2017 Financial Results
Nov 06, 2017 21:03 pm UTC| Business
Third quarter total revenue up 10% from a year ago to $82.4 million.Third quarter net loss of $(9.5) million, or $(0.10) per share, compared to net loss of $(7.4) million, or $(0.09) per share, in the third quarter of...
Nov 06, 2017 21:03 pm UTC| Business
- FDA decision on New Drug Application expected by June 30, 2018 - Licensed exclusive, worldwide rights to lebrikizumab from Roche - Completed patient enrollment in two Phase 3 trials for the treatment of acne...
UK Inflation Stabilizes: November CPI at 2.6%, Signaling Economic Recovery
FDA Approval of Opdivo Injection Sparks Hope for Cancer Patients with Revolutionary Treatment Update